Date: 0000-00-00
Type of information: Resignation
Compound:
Company: Bluebird bio (USA - MA)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On February 25, 2016, bluebird bio announced that Jim DeTore, chief financial officer, has decided to leave the company, effective March 18, 2016. In conjunction with this announcement, bluebird bio is appointing Jeffrey Walsh as chief financial and strategy officer, effective March 1, 2016. Mr. Walsh previously served as chief operating officer of bluebird bio since May 2011. Prior to joining bluebird bio, Mr. Walsh served as chief business officer of Taligen Therapeutics. He has also held senior business development, finance and operations roles at PathoGenesis Corp. (acquired by Chiron Corporation), AllScripts Healthcare Solutions, EXACT Sciences and Inotek Pharmaceuticals.
Financial terms:
Latest news:
